|
EQS-News: Pentixapharm AG / Key word(s): Personnel Pentixapharm Announces Expansion of Supervisory Board with the Appointment of Distinguished Endocrinologist Marcus Quinkler 01.07.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Pentixapharm Announces Expansion of Supervisory Board with the Appointment of Distinguished Endocrinologist Marcus Quinkler Würzburg and Berlin, Germany July 1st, 2024 – Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a broad range of malignancies, announced today that the General Shareholder Meeting of Pentixapharm resolved the appointment of the distinguished endocrinologist Prof. Dr. med. Marcus Quinkler to the Company’s Supervisory Board. The assignment will become effective with the registration of the split-off of Pentixapharm AG from Eckert & Ziegler SE in the commercial register. “We welcome Marcus Quinkler as a valuable addition to our Board. He is a recognized expert among others in primary aldosteronism, the focus area of our Phase III lead program PENTIXAFOR (PTF-302). He will also help Pentixapharm to advance its ongoing clinical assessments of the Company’s novel, CXCR4-based radiopharmaceutical therapeutic and diagnostic programs.” explained Dr. Hakim Bouterfa, Founder and Chief Executive Officer of the Pentixapharm Holding AG. Marcus Quinkler is a specialist of internal medicine and endocrinology, diabetology and andrology. Formerly at the endocrinology department at the Charité-Universitätsmedizin, Campus Mitte, Berlin, currently leading a specialized endocrine practice in Berlin, Dr. Quinkler has significantly contributed to the field, serving as an adjunct professor at Charité. His academic training includes a medical degree and doctorate from the Free University of Berlin, a research fellowship at the University of Birmingham, U.K., funded by the DFG, and a postdoctoral thesis at the Charité to qualify as a professor. Dr. Quinkler has led significant clinical guideline developments and held editorial roles in prominent journals. His accolades include the Schoeller-Junkmann Prize and the Arthur-Jores Honorary Prize from the German Society for Endocrinology (DGE). From 1996 to 2024, Dr. Quinkler has authored over 270 peer-reviewed publications. Dr. Marcus Quinkler added: “Pentixapharm’s CXCR4-ligand technologies are being evaluated not only in hematological indications but also for a range of other applications beyond cancer. Notably, their advanced diagnostic program in Primary Aldosteronism holds significant promise as a meaningful alternative to the current gold standard, potentially improving patient outcomes and enhancing cardiovascular health. I am pleased to join the Board at this pivotal moment and support the Company in their future growth.” Dr. Quinkler will strengthen the Supervisory Board of Pentixapharm AG next to Chairman Dr. Andreas Eckert, Jens Giltsch and Dr. Harald Hasselmann, who also serves as CEO of Eckert & Ziegler SE. About Pentixapharm AG Pentixapharm is a radiopharmaceutical development company founded in 2019 with its headquarters in Würzburg, Germany. It is currently wholly owned by the Eckert & Ziegler Group but bound to be spun-off to the Frankfort Stock Exchange soon. Pentixapharm is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular and endocrine diseases. Pentixapharm’s clinical program encompasses PENTIXATHER, am Yttrium-90 based therapeutic against CNS lymphoma, and PENTIXAFOR, a Gallium-68 based companion diagnostic. Clinical studies for both compounds have already commenced in Europe, with a dose-finding study for PENTIXATHER and a Phase III registration study for PENTIXAFOR. Additionally, PENTIXAFOR is being developed as a diagnostic tool for primary aldosteronism, a significant cause of hypertension. Pentixapharm aims to initiate an advanced clinical trial in the United States in 2025. For more information, please contact: Eckert & Ziegler SE Pentixapharm AG Media Contact: 01.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Melanoma: Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug
April 19, 2024